HIND (Vyome Holdings Inc) Short-Term Debt to Capital

Vyome Holdings Inc (HIND) bases its operations on developing therapies for skin pathologies and inflammatory processes within US laboratories. The current stage of development is complicated by the consolidation of various medical divisions and a liquidity shortage, necessitating an increase in device sales. Meanwhile, the business relies on external financing due to a lack of profitability and uncertainty regarding trial results, with the indicator standing at 0.00. This price chart on the GURU.Markets platform clearly illustrates these market risks.

This ratio assesses the company's dependence on liabilities maturing within one year relative to its equity, where increasing values signal liquidity risk. By analyzing the short-term debt-to-equity chart, an investor determines the ability of Vyome Holdings Inc. (HIND) to fund the development of its molecular design platform for combating resistant skin infections without imposing a critical debt burden on its assets.